
|Articles|August 1, 2006
- Pharmaceutical Executive-08-01-2006
- Volume 0
- Issue 0
How Far We've Come
In 1981, pharma was a more innocent industry. It stood on the brink of an AIDS epidemic that science had yet to name or understand. Hazards of generics, product lifecycles, and off-label marketing lay years ahead. There were no embryonic stem cells to fight over--nor euphemisms like "overactive bladder syndrome" and "erectile dysfunction" to ease conversations or kick off ad campaigns. Who knew what awaited us? To remember--and to reflect on what shaped modern pharma--we invite you to page through the most significant events of the past quarter century.
Advertisement
Articles in this issue
about 20 years ago
Time Machineabout 20 years ago
Getting Betterabout 20 years ago
States Curb Marketingabout 20 years ago
From the Editor: Take Your Seatabout 20 years ago
Viewpoint: In Your Wordsabout 20 years ago
Quiz Answersabout 20 years ago
Introduction: Pharm Exec at 25Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma
5




